LYRA   $0.24  4.35% Market Closed After Close 0.249 3.75%

Lyra Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-09 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-05 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-05 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.


Current temperature: 5.41
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 1.25
Mean unverified/preliminary 1.25 / 1.25
Target Price Low / High 0.50 / 2.00
Median / STD DEV 1.25 / 1.06
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy Buy
rsi ActivelyBuy None None
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 Sell Buy None
ma50 ActivelyBuy None None
ma100 Sell Buy ActivelyBuy
Candlestick PatternOct. 10, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US55234L1052
ceo Dr. Maria Palasis Ph.D.
Website https://lyratherapeutics.com
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.